Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Amortizatization of Intangibles (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Amortizatization of Intangibles for 5 consecutive years, with $21823.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles changed 0.0% year-over-year to $21823.0, compared with a TTM value of $86823.0 through Dec 2025, up 325.11%, and an annual FY2025 reading of $86823.0, changed 0.0% over the prior year.
  • Amortizatization of Intangibles was $21823.0 for Q4 2025 at SAB Biotherapeutics, up from $21294.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $41259.0 in Q1 2021 and bottomed at -$104393.0 in Q3 2024.
  • Average Amortizatization of Intangibles over 5 years is $21784.3, with a median of $23858.0 recorded in 2022.
  • The sharpest move saw Amortizatization of Intangibles crashed 574.51% in 2024, then skyrocketed 120.4% in 2025.
  • Year by year, Amortizatization of Intangibles stood at $41206.0 in 2021, then tumbled by 40.02% to $24716.0 in 2022, then rose by 21.38% to $30000.0 in 2023, then decreased by 27.25% to $21824.0 in 2024, then decreased by 0.0% to $21823.0 in 2025.
  • Business Quant data shows Amortizatization of Intangibles for SABS at $21823.0 in Q4 2025, $21294.0 in Q3 2025, and $22000.0 in Q2 2025.